Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Location: France, Ile-de-France
Employees: 11-50
Total raised: $38.84M
Founded date: 2014
Investors 5
| Date | Name | Website |
| 22.07.2021 | Seroba Lif... | seroba-lif... |
| - | V-Bio Vent... | v-bio.vent... |
| 25.11.2021 | Kurma Part... | kurmapartn... |
| 25.03.2022 | Turenne Ca... | turennecap... |
| - | GO Capital... | gocapital.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2021 | Series B | $38.84M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 15.06.2023 | Coave Therapeutics announces Positive 12-months Data from On... | Paris, France. 31 May 2023. Seroba portfolio company, Coave Therapeutics (‘Coave’), a clinical-stage... | seroba-lif... |
| 20.09.2022 | Coave Therapeutics to Collaborate with World-Renowned Instit... | Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bor... | fundplus.b... |
| 16.09.2021 | Coave Therapeutics and Théa Open Innovation sign exclusive l... | Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commerciali... | fundplus.b... |
| 22.07.2021 | Coave Therapeutics Closes €33 million ($39 million) Series B... | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy P... | fundplus.b... |
| 21.07.2021 | Coave raises $25M ahead of pivotal retinal gene therapy tria... | Coave Therapeutics has added €21.2 ($25.0 million) million to its series B round, setting the French... | fiercebiot... |
| 21.07.2021 | Coave Therapeutics Closes €33M in Series B Financing | Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing... | finsmes.co... |
| - | Coave Therapeutics Closes €33 million ($39 million) Series B... | Paris, France – 21st July 2021. • Coave Therapeutics is the new name for Horama and reflects its ne... | seroba-lif... |